Sorafenib pre-treatment in patients undergoing Hepatic Arterial Chemo-Embolization (HACE) for unresectable hepatoma to increase tumor kill.
http://clinicaltrials.gov/ct2/show/NCT00949182
Sorafenib tosylate (Nexavar®), a small molecule Raf kinase and VEGF receptor kinase inhibitor, is FDA approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC). However, further data are needed to determine the optimal combination with resection or ablative treatment the maximize survival advantage.
The liver disease center at the New Jersey Medical School is recruiting patients for a pilot phase II clinical trial to assess the use of sorafenib to reduce micro angiogenesis prior to hepatic-arterial-chemo-embolization (HACE) macro-arteriolar blockade. Patient are treated with 14 days of Sorafenib prior to HACE, and Sorafenib is continued after HACE. Sorafenib is continued through out subsequent HACE treatments. Out come measures are safety, number of HACE treatments to obtain a complete response, time to progression and progression free survival.
Treatment Algorithm of Sorafenib Prior to HACE Protocol
Any patient with HCC who is eligible for HACE is eligible for this protocol. A full description will available at ClinicalTrials.gov protocol ID NCT00949182
Contact our study research associate Ismael Castaneda MD at 973-972-6812 or call myself at 973-972-0607 for more information
http://clinicaltrials.gov/ct2/show/NCT00949182
Sorafenib tosylate (Nexavar®), a small molecule Raf kinase and VEGF receptor kinase inhibitor, is FDA approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC). However, further data are needed to determine the optimal combination with resection or ablative treatment the maximize survival advantage.
The liver disease center at the New Jersey Medical School is recruiting patients for a pilot phase II clinical trial to assess the use of sorafenib to reduce micro angiogenesis prior to hepatic-arterial-chemo-embolization (HACE) macro-arteriolar blockade. Patient are treated with 14 days of Sorafenib prior to HACE, and Sorafenib is continued after HACE. Sorafenib is continued through out subsequent HACE treatments. Out come measures are safety, number of HACE treatments to obtain a complete response, time to progression and progression free survival.
Treatment Algorithm of Sorafenib Prior to HACE Protocol
Any patient with HCC who is eligible for HACE is eligible for this protocol. A full description will available at ClinicalTrials.gov protocol ID NCT00949182
Contact our study research associate Ismael Castaneda MD at 973-972-6812 or call myself at 973-972-0607 for more information